To test or not to test: Understanding prostate cancer screening and early detection

Sometimes there is no perfect answer in medicine, and prostate cancer screening remains one of those complex issues. The subject has recently returned to the headlines, and many people continue to ask questions about it, which suggests there is still considerable confusion surrounding prostate cancer testing, PSA test reliability, and the role of modern MRI scans in early diagnosis. Understanding your options and symptoms is the first step toward proactive men’s health management.

To begin at the beginning: what exactly is cancer? The term itself is something of a catch-all description for a wide range of diseases. In simple terms, cancer occurs when cells begin to grow and divide uncontrollably. Instead of dying naturally, as healthy cells should, they continue multiplying and can eventually spread into surrounding tissues and other organs. This process is known as metastasis.

There are more than 100 different diseases classified as cancer, and they vary enormously. Some cancers develop rapidly, while others progress very slowly. Research continues to advance at an impressive pace, and developments in genetic and DNA technology are helping clinicians better understand these diseases than ever before.

One principle, however, remains consistent: the earlier cancer is detected, the greater the chance of successful treatment. Some cancers produce warning signs early on, while others remain silent for years. The ultimate goal of screening is therefore to identify cancer at the earliest possible stage, when intervention is most effective.

The anatomy of the prostate and early signs

Prostate cancer presents a particular challenge. The prostate is a gland found only in men and plays an important role in reproduction. Anatomically, it sits deep within the pelvis and surrounds the urethra – the tube that carries urine from the bladder out of the body. The prostate also helps regulate the flow of urine, making it an important part of the male urinary system.

The controversy surrounding prostate cancer screening centres on the PSA test. PSA stands for Prostate-Specific Antigen, a protein produced by prostate cells. The test itself is simple: a routine blood sample that can usually provide results within a few days.

However, the PSA test is only the first stage of assessment. An elevated PSA level does not necessarily mean a man has prostate cancer. It is only one piece of the overall clinical picture.

The prostate naturally changes in size with age. In younger men, it is often compared to the size of a walnut, but it can enlarge significantly over time. As the gland grows, it may begin to compress the urethra, making urination more difficult. It can also press against the bladder, creating a frequent or urgent need to urinate, particularly during the night. These symptoms are common and do not automatically indicate cancer – although in some cases they may warrant further investigation.

This brings us back to a key principle of cancer care: early detection improves outcomes. Prostate cancer is often highly treatable when identified early.

Treatment options and active surveillance

In some cases, particularly with very slow-growing tumours, doctors may recommend active surveillance rather than immediate treatment. Depending on a patient’s age and overall health, careful monitoring may be entirely appropriate. Medications can also help relieve urinary symptoms.

In other cases, treatment depends on how advanced the cancer is and the level of risk it poses. Some therapies are designed to slow tumour growth, while radiotherapy can destroy cancer cells directly within the prostate. In certain situations, surgical removal of the prostate may be the best option.

The difficulty arises when prostate cancer is not detected early enough. Like many cancers, it can spread to other parts of the body, at which point treatment becomes far more difficult. In the United Kingdom, prostate cancer remains the second leading cause of cancer-related death among men, underlining the importance of taking the disease seriously.

Much of the debate reported in the media concerns the limitations of the PSA test. A raised PSA result alone is not sufficient to diagnose cancer, which means further investigations may be required. Traditionally, the next step after consultation with a urologist was often a biopsy.

Understanding the risks of traditional biopsies

A biopsy involves taking a small tissue sample from the prostate for microscopic examination. Accessing the prostate is not straightforward, and the procedure carries some risks, including:

• Infection

• Urinary incontinence

• Erectile dysfunction

Although these risks are relatively low, they are important considerations, and no patient should ever feel pressured into undergoing the procedure without fully understanding the implications.

Fortunately, diagnostic approaches have improved significantly in recent years.

The modern solution: MRI as the gold standard

Today, many patients are offered an MRI scan before a biopsy is considered. During an MRI scan, the patient lies inside a scanning machine while detailed three-dimensional images of internal organs are produced. Although MRI scanners were once limited in availability, they are now widely accessible and provide clinicians with highly detailed information. MRI imaging is now regarded as the gold standard in the assessment of suspected prostate cancer.

MRI scans can identify slow-growing tumours that may safely be monitored rather than treated immediately. If the scan is completely clear, invasive testing may not be necessary. If abnormalities are detected, any subsequent biopsy can be performed with much greater precision, significantly reducing the need for random sampling and limiting potential complications.

Who should consider a prostate cancer test?

So, what should men do?

Medical guidance has evolved over time. Previously, PSA testing was often recommended only after symptoms developed – although by that stage, opportunities for early treatment may already have been reduced. One reason for caution was the relatively high rate of false-positive PSA results.

With the increased availability and accuracy of MRI scanning, the approach is changing.

• Men over the age of 55: Should strongly consider having a PSA test and discussing the results with a consultant urologist if levels are elevated.

• Men between 40 and 55: Who experience urinary difficulties or frequent night time urination should also consider arranging a PSA test.

Breaking the stigma around men’s health

Cancer is understandably frightening and should never be dismissed lightly. The encouraging reality is that prostate cancer is often highly treatable, particularly when diagnosed early. While the PSA test is not perfect, it remains an important first step. Combined with modern MRI imaging, it forms the most effective diagnostic pathway currently available.

Finally, a word to the men reading this: your GP has dealt with these conversations countless times before. Feeling embarrassed is entirely natural, but there is no reason to avoid seeking advice. If you would feel more comfortable speaking to a male doctor, you are fully entitled to request one. Most practices will accommodate this, even if it means waiting slightly longer for an appointment. What matters most is not delaying the conversation.

The information provided in this column is for educational and informational purposes only, and does not constitute medical advice. It is not a substitute for a professional medical consultation, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health provider with any questions you may have regarding a medical condition.

Dr Marcus Stephan